Phase I study of recombinant human endostatin in patients with advanced solid tumors.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Journal of Clinical Oncology

• Publication date

  2002-09-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2002.11.061PMID 12228199
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Zinc ligand-disrupted recombinant human Endostatin: Potent inhibition of tumor growth, safety and pharmacokinetic profile

  2004cited by this paper
• Angiostatin and Endostatin: Endogenous Inhibitors of Tumor Growth

  2004cited by this paper
• Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer.

  2002cited by this paper
• Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin.

  2002cited by this paper
• Study of the media's potential influence on prospective research participants' understanding of and motivations for participation in a high-profile phase I trial.

  2002cited by this paper
• Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors.

  2002cited by this paper
• In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy

  2001cited by this paper
• Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer.

  2001cited by this paper
• The Nc1/Endostatin Domain of Caenorhabditis elegans Type Xviii Collagen Affects Cell Migration and Axon Guidance

  2001cited by this paper
• A polymorphism in endostatin, an angiogenesis inhibitor, predisposes for the development of prostatic adenocarcinoma.

  2001cited by this paper
• Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model.

  2001cited by this paper
• Endostatin Binds Tropomyosin

  2001cited by this paper
• Clinical trial designs for cytostatic agents: are new approaches needed?

  2001cited by this paper
• Interaction of endostatin with integrins implicated in angiogenesis.

  2001cited by this paper
• Serum endostatin levels are elevated in patients with soft tissue sarcoma

  2001cited by this paper
• In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy

  2001cited by this paper
• Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy.

  2000cited by this paper
• Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer.

  2000cited by this paper
• Fractals and cancer.

  2000cited by this paper
• Serum endostatin levels in patients with hepatocellular carcinoma.

  2000cited by this paper
• Serum soluble vascular cell adhesion molecule-1: role as a surrogate marker of angiogenesis.

  2000cited by this paper
• Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model.

  1998cited by this paper
• Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. The Michel Clavel Lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, 16-19 June 1998.

  1998cited by this paper
• Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance

  1997cited by this paper
• Endostatin: an endogenous inhibitor of angiogenesis and tumor growth.

  1997cited by this paper
• Angiostatin induces and sustains dormancy of human primary tumors in mice

  1996cited by this paper
• Cloning of cDNA and genomic DNA encoding human type XVIII collagen and localization of the alpha 1(XVIII) collagen gene to mouse chromosome 10 and human chromosome 21.

  1994cited by this paper
• Vascular targeting and the inhibition of angiogenesis.

  1994cited by this paper
• The implications of angiogenesis for the biology and therapy of cancer metastasis.

  1994cited by this paper
• What is the evidence that tumors are angiogenesis dependent?

  1990cited by this paper
• Tumor angiogenesis.

  1974cited by this paper

• Anti-angiogenic therapies in cancer: from endogenous inhibitors to bispecific VEGF x PD-(L)1 antibodies

  2026cites this paper
• Endostatin in disease modulation: From cancer to beyond.

  2024cites this paper
• Recombinant human endostatin as a potential anti-angiogenic agent: therapeutic perspective and current status

  2023cites this paper
• The Preventive Effect of Endostar on Radiation-Induced Pulmonary Fibrosis.

  2023cites this paper
• Cell surface nucleolin is a novel ADAMTS5 receptor mediating endothelial cell apoptosis

  2022cites this paper
• A functional outside-in signaling network of proteoglycans and matrix molecules regulating autophagy.

  2021cites this paper
• Tolerance and Pharmacokinetics of Recombinant Human Endostatin Administered as Single-Dose or Multiple-Dose Infusions in Patients With Advanced Solid Tumors: A Phase I Clinical Trial

  2021cites this paper
• Exploring the roles of MACIT and Multiplexin collagens in stem cells and cancer.

  2020cites this paper
• Microenvironmental Heterogeneity Among Triple-Negative Breast Cancer Subtypes and the Promise of Precision Medicine

  2020cites this paper
• Microenvironmental heterogeneity among triple negative breast cancer subtypes and the promise of precision medicine.

  2019cites this paper
• Recombinant Human Endostatin against the development of RIPF in a murine model

  2019cites this paper
• Activated Signaling Pathways and Targeted Therapies in Desmoid-Type Fibromatosis: A Literature Review

  2019cites this paper
• Cancer Angiogenesis

  2019cites this paper
• CD31‐labeled circulating endothelial cells as predictor in anlotinib‐treated non‐small‐cell lung cancer: Analysis on ALTER‐0303 study

  2018cites this paper
• The Evaluation of Durative Transfusion of Endostar Combined with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer

  2018cites this paper
• RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells

  2018cites this paper
• Enhanced expression of Vastatin inhibits angiogenesis and prolongs survival in murine orthotopic glioblastoma model

  2017cites this paper
• Synergistic effects of the combination of Endostar and radiotherapy against hepatocellular carcinoma in a mouse model

  2017cites this paper
• 2 Resistance to Apoptosis in Cancer Therapy

  2017cites this paper
• Biomarker-based Diagnosis and Personalized Medicine for Cancer Patients: Trinity of Nucleolin Guided, Endostatin Treatment, and Plasma Hsp90α Monitored

  2017cites this paper
• Therapeutic Agents That Inhibit Angiogenesis

  2017cites this paper
• Vastatin, an Endogenous Antiangiogenesis Polypeptide That Is Lost in Hepatocellular Carcinoma, Effectively Inhibits Tumor Metastasis.

  2016cites this paper
• educed Pericardial Levels of ndostatin Correlate With Collateral evelopment in Patients With Ischemic Heart Disease

  2016cites this paper
• Antiangiogenic therapy in oncology: current status and future directions.

  2016cites this paper
• Pericardial Levels of ndostatin Correlate With Collateral evelopment in Patients With Ischemic Heart Disease

  2016cites this paper
• Endostatin and endorepellin: A common route of action for similar angiostatic cancer avengers.

  2016cites this paper
• Sp1-driven up-regulation of miR-19a decreases RHOB and promotes pancreatic cancer

  2015cites this paper
• Extension of the in vivo half-life of endostatin and its improved anti-tumor activities upon fusion to a humanized antibody against tumor-associated glycoprotein 72 in a mouse model of human colorectal carcinoma

  2015cites this paper
• Endostar inhibits ascites formation and prolongs survival in mouse models of malignant ascites.

  2015cites this paper
• Phase II trial of recombinant human endostatin in combination with concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer.

  2015cites this paper
• Phase I Trials Today

  2015cites this paper
• Antiangiogenesis beyond VEGF inhibition: a journey from antiangiogenic single-target to broad-spectrum agents.

  2014cites this paper
• A highly recurrent RPS27 5'UTR mutation in melanoma

  2014cites this paper
• Incidence and clinical implication of tumor cavitation in patients with advanced non‐small cell lung cancer induced by Endostar, an angiogenesis inhibitor

  2014cites this paper
• Optically-Active Nanomaterials for Diagnostic and Therapeutic Applications in Ovarian Cancer

  2014cites this paper
• Phase I trial of M2ES, a novel polyethylene glycosylated recombinant human endostatin, plus gemcitabine in advanced pancreatic cancer.

  2014cites this paper
• Expression of liver-targeting peptide modified recombinant human endostatin and preliminary study of its biological activities

  2014cites this paper
• PET imaging of neovascularization with (68)Ga-3PRGD2 for assessing tumor early response to Endostar antiangiogenic therapy.

  2014cites this paper
• Beyond anti-VEGF: dual-targeting antiangiogenic and antiproliferative therapy.

  2013cites this paper
• Effects of the C-terminal of endostatin on the tumorigenic potential of H22 cells.

  2013cites this paper
• A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma.

  2013cites this paper
• Antiangiogenesis Effects of Endostatin in Retinal Neovascularization

  2013cites this paper
• Normal and abnormal pulmonary arteriovenous shunting: occurrence and mechanisms

  2013cites this paper
• Elevated serum endostatin levels are associated with poor survival in patients with advanced-stage nasopharyngeal carcinoma.

  2013cites this paper
• Circulating endothelial cells and tumor blood volume as predictors in lung cancer

  2013cites this paper
• Synergistic Antiangiogenic Activity of Tetrandrine Combined with Endostar on the Human Umbilical Vein Endothelial Cell Model

  2013cites this paper
• Tumor perfusie door middel van First-Pass F-18 FDG PET beelden

  2012cites this paper
• Endostatin, an Inhibitor of Angiogenesis, Decreases After Bidirectional Superior Cavopulmonary Anastamosis

  2012cites this paper
• Effect of endostatin on 1,2-dimethylhydrazine-induced colon tumor in mice

  2012influential citation
• Enhanced anti-angiogenesis and anti-tumor activity of endostatin by chemical modification with polyethylene glycol and low molecular weight heparin.

  2012cites this paper
• Tumor endothelial markers as a target in cancer

  2012cites this paper
• Systems Biology of Pancreatic Cancer: The Role of Tumor-Microenvironment Communication in Development, Progression and Therapy Resistance

  2012cites this paper
• Antiangiogenic and anticancer molecules in cartilage

  2012cites this paper
• Molecular Alterations Associated with Osteosarcoma Development

  2012cites this paper
• Tumorigenesis in Down's syndrome: big lessons from a small chromosome

  2012cites this paper
• Applications of Positron Emission Tomography in the Development of Molecular Targeted Cancer Therapeutics

  2012cites this paper
• Anti-angiogenic drug discovery: lessons from the past and thoughts for the future

  2012cites this paper
• Dynamic Contrast-Enhanced MR Imaging in a Phase Ⅱ Study on Neoadjuvant Chemotherapy Combining Rh-Endostatin with Docetaxel and Epirubicin for Locally Advanced Breast Cancer

  2012cites this paper
• Preparation, characterization and anti-angiogenesis activity of endostatin covalently modified by polysulfated heparin.

  2012cites this paper
• Skeletal muscle matrix metalloproteinase and exercise in humans

  2011cites this paper
• Targeted Delivery of an Antibody–Mutant Human Endostatin Fusion Protein Results in Enhanced Antitumor Efficacy

  2011cites this paper
• Integrin-Mediated Cell-Matrix Interaction in Physiological and Pathological Blood Vessel Formation

  2011cites this paper
• Osteopontin and Endostatin Concentrations in Peripheral Blood of Patients with Adrenal Tumors Undergoing Unilateral Adrenalectomy

  2011cites this paper
• Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase

  2011cites this paper
• Angiogenesis and Lung Cancer

  2011cites this paper
• Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium derived factor make low molecular weight heparin-endostatin and polyethylene glycol-endostatin potential candidates for anti-angiogenesis drug.

  2011cites this paper
• Tumor Angiogenesis as a Target for Dietary Cancer Prevention

  2011cites this paper
• Improvement in the standard treatment for experimental glioma by fusing antibody Fc domain to endostatin.

  2011cites this paper
• 1 Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin-Cytosine Deaminase-Uracil Phosphoribosyl Transferase

  2011cites this paper
• Angiogenesis regulation in hormone dependent breast- and ovarian cancer

  2011cites this paper
• Endostatin specifically targets both tumor blood vessels and lymphatic vessels

  2011cites this paper
• Classification of Anticancer Drugs Based on Therapeutic Targets

  2010cites this paper
• Novel agents in the management of lung cancer.

  2010cites this paper
• Endogenous Matrix-Derived Inhibitors of Angiogenesis

  2010cites this paper
• p53 and Angiogenesis

  2010cites this paper
• Endostatin inhibits tumour lymphangiogenesis and lymphatic metastasis via cell surface nucleolin on lymphangiogenic endothelial cells

  2010cites this paper
• Vascular integrins: therapeutic and imaging targets of tumor angiogenesis.

  2010cites this paper
• Perspectives in the development of novel treatment approaches.

  2010cites this paper
• Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors.

  2010cites this paper
• The effect of endostatin mediated by human mesenchymal stem cells on ovarian cancer cells in vitro

  2010cites this paper
• Biomarkers of response to angiogenesis inhibitors: an open and unsolved question.

  2010cites this paper
• Expression of b‐FGF and endostatin and their clinical significance in human osteosarcoma

  2010cites this paper
• The N-terminal integrity is critical for the stability and biological functions of endostatin.

  2010cites this paper
• Rhabdoid Tumor: Gene Expression Clues to Pathogenesis and Potential Therapeutic Targets

  2010cites this paper
• Tumor Angiogenesis: Insights and Innovations

  2010cites this paper
• Tumor-targeted delivery of biologically active TRAIL protein

  2010cites this paper
• Tumor vasculature as target for therapeutic intervention

  2010cites this paper
• Tumour targeting with systemically administered bacteria.

  2010cites this paper
• Cationic liposome coupled endostatin gene for treatment of peritoneal colon cancer

  2010cites this paper
• Bacteria as vectors for gene therapy of cancer

  2010cites this paper
• Recombinant human endostatin improves anti-tumor efficacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma

  2010cites this paper
• Unraveling the mysteries of endostatin

  2009cites this paper
• Therapeutic effects of recombinant human endostatin adenovirus in a mouse model of malignant pleural effusion

  2009cites this paper
• Therapeutic efficacy of Bifidobacterium longum‐mediated human granulocyte colony‐stimulating factor and/or endostatin combined with cyclophosphamide in mouse‐transplanted tumors

  2009cites this paper
• The dynamics of tumour–vasculature interaction suggests low‐dose, time‐dense anti‐angiogenic schedulings

  2009cites this paper
• The use of endostatin in the treatment of solid tumors.

  2009cites this paper
• The use of endostatin in the treatment of solid tumors

  2009cites this paper
• Current status and future prospects for anti-angiogenic therapies in cancer

  2009cites this paper
• Discrepancies Between Antiangiogenic and Antitumor Effects of Recombinant Human Endostatin

  2009cites this paper
• Thrombosis associated with angiogenesis inhibitors.

  2009cites this paper